179 related articles for article (PubMed ID: 11439210)
1. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors.
Murata R; Siemann DW; Overgaard J; Horsman MR
Radiother Oncol; 2001 Aug; 60(2):155-61. PubMed ID: 11439210
[TBL] [Abstract][Full Text] [Related]
2. Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy.
Murata R; Overgaard J; Horsman MR
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):1018-24. PubMed ID: 11704326
[TBL] [Abstract][Full Text] [Related]
3. Preclinical studies to predict efficacy of vascular changes induced by combretastatin a-4 disodium phosphate in patients.
Nielsen T; Murata R; Maxwell RJ; Stødkilde-Jørgensen H; Ostergaard L; Horsman MR
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):859-66. PubMed ID: 18164835
[TBL] [Abstract][Full Text] [Related]
4. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy.
Li L; Rojiani A; Siemann DW
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):899-903. PubMed ID: 9845118
[TBL] [Abstract][Full Text] [Related]
5. Early effects of combretastatin-A4 disodium phosphate on tumor perfusion and interstitial fluid pressure.
Ley CD; Horsman MR; Kristjansen PE
Neoplasia; 2007 Feb; 9(2):108-12. PubMed ID: 17356706
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma.
Li L; Rojiani AM; Siemann DW
Acta Oncol; 2002; 41(1):91-7. PubMed ID: 11990525
[TBL] [Abstract][Full Text] [Related]
7. The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors.
Horsman MR; Ehrnrooth E; Ladekarl M; Overgaard J
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):895-8. PubMed ID: 9845117
[TBL] [Abstract][Full Text] [Related]
8. Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues.
Murata R; Overgaard J; Horsman MR
Int J Radiat Biol; 2001 Feb; 77(2):195-204. PubMed ID: 11236926
[TBL] [Abstract][Full Text] [Related]
9. Combretastatins novel vascular targeting drugs for improving anti-cancer therapy. Combretastatins and conventional therapy.
Horsman MR; Murata R; Breidahl T; Nielsen FU; Maxwell RJ; Stødkiled-Jørgensen H; Overgaard J
Adv Exp Med Biol; 2000; 476():311-23. PubMed ID: 10949676
[TBL] [Abstract][Full Text] [Related]
10. Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid.
Murata R; Siemann DW; Overgaard J; Horsman MR
Radiat Res; 2001 Nov; 156(5 Pt 1):503-9. PubMed ID: 11604063
[TBL] [Abstract][Full Text] [Related]
11. Segmentation of dynamic contrast enhanced magnetic resonance imaging data.
Nielsen T; Mouridsen K; Maxwell RJ; Stødkilde-Jørgensen H; Østergaard L; Horsman MR
Acta Oncol; 2008; 47(7):1265-70. PubMed ID: 18661437
[TBL] [Abstract][Full Text] [Related]
12. Combination of vascular targeting agents with thermal or radiation therapy.
Horsman MR; Murata R
Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1518-23. PubMed ID: 12459380
[TBL] [Abstract][Full Text] [Related]
13. The effect of combretastatin A4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on water diffusion and blood perfusion in tumours.
Chen G; Horsman MR; Pedersen M; Pang Q; Stødkilde-Jørgensen H
Acta Oncol; 2008; 47(6):1071-6. PubMed ID: 18770061
[TBL] [Abstract][Full Text] [Related]
14. Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response.
Horsman MR; Murata R
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):1047-55. PubMed ID: 14575836
[TBL] [Abstract][Full Text] [Related]
15. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy.
Siemann DW; Mercer E; Lepler S; Rojiani AM
Int J Cancer; 2002 May; 99(1):1-6. PubMed ID: 11948484
[TBL] [Abstract][Full Text] [Related]
16. Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation.
Bertelsen LB; Shen YY; Nielsen T; Stødkilde-Jørgensen H; Lloyd GK; Siemann DW; Horsman MR
Int J Radiat Biol; 2011 Nov; 87(11):1126-34. PubMed ID: 21815749
[TBL] [Abstract][Full Text] [Related]
17. Acute effects of vascular modifying agents in solid tumors assessed by noninvasive laser Doppler flowmetry and near infrared spectroscopy.
Kragh M; Quistorff B; Horsman MR; Kristjansen PE
Neoplasia; 2002; 4(3):263-7. PubMed ID: 11988846
[TBL] [Abstract][Full Text] [Related]
18. The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: a comparative assessment using MRI and MRS.
Breidahl T; Nielsen FU; Stødkilde-Jørgensen H; Maxwell RJ; Horsman MR
Acta Oncol; 2006; 45(3):306-16. PubMed ID: 16644574
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of anti-vascular therapy with texture analysis.
Chen G; Jespersen S; Pedersen M; Pang Q; Horsman MR; Stødkilde Jørgensen H
Anticancer Res; 2005; 25(5):3399-405. PubMed ID: 16101155
[TBL] [Abstract][Full Text] [Related]
20. Activity of the vascular targeting agent combretastatin A-4 disodium phosphate in a xenograft model of AIDS-associated Kaposi's sarcoma.
Rojiani AM; Li L; Rise L; Siemann DW
Acta Oncol; 2002; 41(1):98-105. PubMed ID: 11990526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
